Page 44 - Read Online

De Nardi. Mini-invasive Surg 2018;2:20 I http://dx.doi.org/10.20517/2574-1225.2018.30 Page 7 of 7

23. Maurer CA. Urinary and sexual function after total mesorectal excision. Recent Results Cancer Res 2005;165:196-204.
24. Pocard M, Zinzindohoue F, Haab F, Caplin S, Parc R, Tiret E. A prospective study of sexual and urinary function before and after total
mesorectal excision with autonomic nerve preservation for rectal cancer. Surgery 2002;131:368-72.
25. Quah HM, Jayne DG, Eu KW, Seow-Choen F. Bladder and sexual dysfunction following laparoscopically assisted and conventional
open mesorectal resection for cancer. Br J Surg 2002;89:1551-6.
26. Lange MM, van de Velde CJ. Urinary and sexual dysfunction after rectal cancer treatment. Nat Rev Urol 2011;8:51-7.
27. Pachler J, wille-Jorgensen P. Quality of life after rectal resection for cancer, with or without permanent stoma. Cochrane Database Syst
Rev 2005;2:CD004323.
28. Vironen JH, Kairaluoma M, Aalto AM, Kellokumpu IH. Impact of functional results on quality of life after rectal cancer surgery. Dis
Colon Rectum 2006;49:568-78.
29. Pescatori M, Anastasio G, Bottini C. New grading system and scoring for anal incontinence. Evaluation of 335 patients. Dis Colon Rec-
tum 1992;35:482-7.
30. Jorge JM, Wexner SD. Etiology and management of fecal incontinence. Dis Colon Rectum 1993;36:77-97.
31. American Medical Systems. Fecal incontinence scoring system. Minnetonka: American Medical Systems; 1996.
32. Vaizey CJ1, Carapeti E, Cahill JA, Kamm MA. Prospective comparison of faecal incontinence grading systems. Gut 1999;44:77-80.
33. Emmertsen KJ, Laurberg S; Rectal Cancer Function Study Group. Impact of bowel dysfunction on quality of life after sphincter-pre-
serving resection for rectal cancer. Br J Surg 2013;100:1377-87.
34. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JCJM, Kaasa
S, Klee MC, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw KCA, Sullivan M, Takeda F. The European Organization for Research
and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst
1993;85:365-76.
35. Whistance RN, Conroy T, Chie W, Costantini A, Sezer O, Koller M, Johnson CD, Pilkington SA, Arraras J, Ben-Josef E, Pullyblank
AM, Fayers P, Blazeby JM; European Organization for the Research and Treatment of Cancer Quality of Life Group. Clinical and psy-
chometric validation of the EORTC QLQ-CR29 questionnaire module to assess health-related quality of life in patients with colorectal
cancer. Eur J Cancer 2009;45:3017-26.
36. Borreca D, Bona A, Bellomo MP, Borasi A, De Paolis P. The new approach to the rectal cancer: ‘down-to-up’ double endolaparoscopic
pelvic access. Preliminary evaluation of outcomes. Updates Surg 2015;67:293-9.
37. Rouanet P, Mourregot A, Azar, Carrere S, Gutowski M, Quenet F, Saint-Aubert B, Colombo P. Transanal endoscopic proctectomy: an
innovative procedure for difficult resection of rectal tumors in men with narrow pelvis. Dis Colon Rectum 2013;56:408-15.
38. Elmore U, Fumagalli Romario U, Vignali A, Sosa MF, Angiolini MR, Rosati R. Laparoscopic anterior resection with transanal total me-
sorectal excision for rectal cancer: preliminary experience and impact on postoperative bowel function. J Laparopendosc Adv Surg Tech
A 2015;25:364-9.
39. Atallah S, Martin-Perez B, Albert M, deBeche-Adams T, Nassif G, Hunter L, Larach S. Transanal minimally invasive surgery for total
mesorectal excision (TAMIS-TME): results and experience with the first 20 patients undergoing curative-intent rectal cancer surgery at
a single institution. Tech Coloproctol 2014;18:473-80.
40. Tuech JJ, Karoui M, Lelong B, De Chaisemartin C, Bridoux V, Manceau G, Delpero JR, Hanoun L, Michot F. A step toward NOTES
total mesorectal excision for rectal cancer: endoscopic transanal proctectomy. Ann Surg 2015;261:228-33.
41. Kneist W, Wachter N, Paschold M, Kauff D, Rink A, Lang H. Midterm functional results of taTME with neuromapping for low rectal
cancer. Tech Coloproctol 2016;20:41-9.
42. Prestil J, Kane CJ, Shinohara K. Neoplasm of the prostate gland. Smith’s General Urology. 7th ed. 2008. p. 351.
43. Barry MJ, Adolfsson J, Batista-Miranda JE. Committee 6: measuring the symptoms and health impact of benign prostatic hyperplasia
and its treatments. In: Denis L, Griffiths K, Khoury S, editors. Proceedings of the fourth international consultation on benign prostatic
hyperplasia. Plymouth: Health Publication Ltd; 1998. p. 265-321.
44. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimen-
sional scale for assessment of erectile dysfunction. Urology 1997;4:822-30.
45. Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, Ferguson D, D’Agostino R Jr. The female sexual function index (FSFI):
a multidimensional self-report instrumentfor the assessment of female sexual function. J Sex Marital Ther 2000;26:191-208.
46. Whistance RN, Conroy T, Chie W, Costantini A, Sezer O, Koller M, Johnson CD, Pilkington SA, Arraras J, Ben-Josef E, Pullyblank
AM, Fayers P, Blazeby JM; European Organisation for the Research and Treatment of Cancer Quality of Life Group. Clinical and psy-
chometric validation of the EORTC QLQ-CR29 questionnaire module to assess health related quality of life in patients with colorectal
cancer. Eur J Cancer 2009;45:3017-26.
47. Fayers P, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ-C30 Scoring Manual. 3rd ed. Brussels: Euro-
pean Organisation for Research and Treatment of Cancer; 2001.
48. Deijen CL, Velthuis S, Tsai A, Mavroveli S, de Lange-de Klerk ES, Sietses C, Tuynman JB, Lacy AM, Hanna GB, Bonjer HJ. COLOR
III: a multicentre randomised clinical trial comparing transanal TME versus laparoscopic TME for mid and low rectal cancer. Surg En-
dosc 2016;30:3210-5.